Krystal Biotech, Inc. KRYS 深 滬
交易中 09-19 12:32:58 美东时间
190.08
+7.340
+4.02%
華盛通- 最 高190.96
- 今 開187.42
- 成交量 11.30万股
- 最 低 185.415
- 昨 收 182.74
- 總市值 53.78亿
- 52周最高 219.34
- 市盈率 靜 482.56
- 換手率 0.40%
- 52周最低 93.95
- 委 比 -73.91%
- 總股本 2829.26万
- 歷史最高 219.34
- 量 比 0.69
- 振 幅 3.03%
- 歷史最低 8.03
- 每 手 1
- 風險率 34.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多How Is The Market Feeling About Krystal Biotech?
Krystal Biotech's (NYSE:KRYS) short percent of float has fallen 4.6% since its ...
09-11 00:30
Cantor Fitzgerald Reiterates Overweight on Krystal Biotech
Cantor Fitzgerald analyst Josh Schimmer reiterates Krystal Biotech (NASDAQ:KRYS) with a Overweight.
08-29 23:00
Krystal Biotech Reports Promising KB301 Phase 1 Results
Krystal Biotech (KRYS) just unveiled an update. Jeune Aesthetics, Inc., a subsi...
08-29 05:09
Krystal Biotech's Jeune reports promising phase 1 data on wrinkles drug
Krystal Biotech (NASDAQ:KRYS) subsidiary Jeune Aesthetics reported promising phase 1 interim efficacy and safety results for KB301, its candidate for wrinkles and lines. The drug is designed to delive...
08-28 22:42
快讯 | Krystal Biotech Inc - Evercore ISI将目标价从201美元提高至206美元
Krystal Biotech Inc - Evercore ISI Raises Target Price to $206 From $201
08-12 13:44
StepStone stock gaps up after fiscal Q1 earnings exceed consensus
StepStone (NASDAQ:STEP) stock climbed 7.9% in Friday midafternoon trading after the private equity and venture capital firm turned in fiscal Q1 2025 earnings that advanced past the average analyst est...
08-10 02:36
Bristol Myers cited by FDA for misleading claims on Krazati website
Bristol Myers Squibb (NYSE:BMY) has received an "untitled letter" from the U.S. FDA Office of Prescription Drug Promotion over alleged misleading claims being made on a physician website for its cance...
08-08 01:53
快讯 | Krystal Biotech Inc：花旗集团从买入调降为中立。
Krystal Biotech Inc : Citigroup Cuts to Neutral From Buy
08-06 18:11
快讯 | Krystal Biotech Inc: 花旗集团将目标价从195美元上调至204美元。
Krystal Biotech Inc : Citigroup Raises Target Price to $204 From $195
08-06 18:11
Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $208
Chardan Capital analyst Geulah Livshits maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $153 to $208.
08-06 06:31
